

10/589907

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.95	202.87
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.64

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:45:33 ON 22 OCT 2009

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptau122ebb

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'CHEMCATS' AT 12:46:36 ON 22 OCT 2009
FILE 'CHEMCATS' ENTERED AT 12:46:36 ON 22 OCT 2009
COPYRIGHT (C) 2009 American Chemical Society (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.95	202.87
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.64

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.95	202.87
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.64

FILE 'REGISTRY' ENTERED AT 12:46:45 ON 22 OCT 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 OCT 2009 HIGHEST RN 1189242-76-9
DICTIONARY FILE UPDATES: 20 OCT 2009 HIGHEST RN 1189242-76-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

10 / 589907

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stn/gen/stndoc/properties.html>

=> d his

(FILE 'HOME' ENTERED AT 12:37:10 ON 22 OCT 2009)

FILE 'REGISTRY' ENTERED AT 12:39:42 ON 22 OCT 2009

L1 STRUCTURE uploaded
L2 3 S L1
L3 STRUCTURE uploaded
L4 3 S L3
L5 49 S L3 SSS FULL

L6 FILE 'CAPLUS' ENTERED AT 12:43:50 ON 22 OCT 2009
2 S L5

L7 FILE 'CHEMCATS' ENTERED AT 12:44:55 ON 22 OCT 2009
0 S L5

FILE 'REGISTRY' ENTERED AT 12:46:45 ON 22 OCT 2009

```
=> file caplus
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY        SESSION
FULL ESTIMATED COST          0.48          203.35

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE      TOTAL
                                                ENTRY        SESSION
CA SUBSCRIBER PRICE           0.00          -1.64
```

FILE 'CPLUS' ENTERED AT 12:46:58 ON 22 OCT 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETEAMS" FOR DETAILS

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS).

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Oct 2009 VOL 151 ISS 17

FILE LAST UPDATED: 21 Oct 2009 (20091021/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 15
L8 2 L5


=> d 18 1-2 bib abs hitstr

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:962241 CAPLUS
DN 143:266825
TI Preparation of dihydropyridinone derivatives for heart and lung disease treatment
IN Gielen-Haertwig, Heike; Albrecht, Barbara; Bauser, Marcus; Keldenich, Joerg; Li, Volkhart; Pernerstorfer, Josef; Schlemmer, Karl-Heinz; Telan, Leila
PA Bayer Healthcare A.-G., Germany
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005080372	A1	20050901	WO 2005-EP1192	20050205
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2556463	A1	20050901	CA 2005-2556463	20050205
	EP 1720857	A1	20061115	EP 2005-701362	20050205
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	JP 2007523105	T	20070816	JP 2006-553484	20050205
	US 20080045541	A1	20080221	US 2007-589907	20070629
PRAI	EP 2004-3741	A	20040219		
	WO 2005-EP1192	W	20050205		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 143:266825; MARPAT 143:266825

GI



AB The invention relates to novel dihydropyridinone derivs., processes for their preparation, and their use in medicaments, especially for the treatment of


chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development. I was prepared from the corresponding pyridinone-3-carboxylic acid, the synthesis of which is given, and 1-phenylpiperazine. Examples are also given for human neutrophil elastase assays, PMN elastolysis assays, acute lung injury model in rats, and acute myocardial infarction model in rats.

IT	863645-30-1P	863645-32-3P	863645-33-4P
	863645-34-5P	863645-35-6P	863645-37-8P
	863645-38-9P	863645-40-3P	863645-41-4P
	863645-42-5P	863645-43-6P	863645-44-7P
	863645-45-8P	863645-46-9P	863645-48-1P
	863645-51-6P	863645-52-7P	863645-53-8P
	863645-54-9P	863645-55-0P	863645-56-1P
	863645-57-2P	863645-59-4P	863645-60-7P
	863645-61-8P	863645-62-9P	863645-64-1P
	863645-65-2P	863645-68-5P	863645-69-6P
	863645-71-0P	863645-73-2P	863645-74-3P
	863645-75-4P	863645-76-5P	863645-78-7P
	863645-80-1P	863645-81-2P	863645-83-4P
	863645-84-5P	863645-85-6P	863645-88-9P
	863646-00-8P		

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dihydropyridinone derivs. for heart and lung disease treatment)


RN 863645-30-1 CAPLUS

CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-[(4-phenyl-1-piperazinyl)carbonyl]-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-32-3 CAPLUS

CN Benzonitrile, 4-[5-acetyl-3-[(4-cyclohexyl-1-piperazinyl)carbonyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-33-4 CAPLUS

CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-3-[(4-hydroxy-1-piperidinyl)carbonyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-34-5 CAPLUS

CN Benzonitrile, 4-[5-acetyl-3-[(4-cycloheptyl-1-piperazinyl)carbonyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-35-6 CAPLUS

CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-[(4-phenylmethyl)-1-piperidinyl]carbonyl]-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl- (CA INDEX NAME)




RN 863645-37-8 CAPLUS

CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-(4-thiomorpholinylcarbonyl)-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl- (CA INDEX NAME)




RN 863645-38-9 CAPLUS

CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-3-[(4-(2-methoxyethyl)-1-piperazinyl)carbonyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl- (CA INDEX NAME)




RN 863645-40-3 CAPLUS

CN Benzonitrile, 4-[5-acetyl-3-[(4-[2-(dimethylamino)ethyl]-1-piperazinyl]carbonyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-41-4 CAPLUS

CN Benzonitrile, 4-[5-acetyl-3-[(4-(4-fluorophenyl)-1-piperazinyl]carbonyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-42-5 CAPLUS

CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-[(4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]carbonyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-43-6 CAPLUS

CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-[[4-[5-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]carbonyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-44-7 CAPLUS

CN Benzonitrile, 4-[5-acetyl-3-[[4-(4-acetylphenyl)-1-piperazinyl]carbonyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-45-8 CAPLUS

CN Benzonitrile, 4-[5-acetyl-3-[(3,5-dimethyl-1-piperidinyl)carbonyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-46-9 CAPLUS

CN Benzonitrile, 4-[5-acetyl-3-[(3,4-dihydro-2-methyl-1(2H)-quinolinyl)carbonyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-48-1 CAPLUS

CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-[[4-[(2,4,6-trimethylphenyl)methyl]-1-piperazinyl]carbonyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-51-6 CAPLUS

CN Benzonitrile, 4-[5-acetyl-3-[(4-(2-furanylcarbonyl)-1-piperazinyl)carbonyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-52-7 CAPLUS

CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-[[4-(phenylmethyl)-1-piperazinyl]carbonyl]-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-53-8 CAPLUS

CN Benzonitrile, 4-[5-acetyl-3-[[4-[3-(dimethylamino)propyl]-1-piperazinyl]carbonyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-54-9 CAPLUS

CN Benzonitrile, 4-[5-acetyl-3-[(4-cyclopentyl-1-piperazinyl)carbonyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-55-0 CAPLUS

CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-[(4-(4-pyridinyl)-1-piperazinyl]carbonyl]-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-56-1 CAPLUS

CN Benzonitrile, 4-[5-acetyl-3-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)carbonyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-57-2 CAPLUS

CN Benzonitrile, 4-[5-acetyl-3-[(hexahydro-1H-azepin-1-yl)carbonyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-59-4 CAPLUS

CN Benzonitrile, 4-[5-acetyl-3-[(1,4'-bipiperidin]-1'-ylcarbonyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-60-7 CAPLUS

CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-3-[(3-(1-methyl-2-pyrrolidinyl)-1-piperidinyl)carbonyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-61-8 CAPLUS


CN 2-Piperidinecarboxylic acid, 1-[(5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl)carbonyl]-, ethyl ester (CA INDEX NAME)




RN 863645-62-9 CAPLUS
CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-3-[(3-methyl-1-piperidinyl)carbonyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)



RN 863645-64-1 CAPLUS
CN Benzonitrile, 4-[5-acetyl-3-[(4-chlorophenyl)methyl]-1-piperazinyl]carbonyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-65-2 CAPLUS
CN Benzonitrile, 4-[5-acetyl-3-[(hexahdropyrrolo[1,2-a]pyrazin-2(1H)-yl)carbonyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-68-5 CAPLUS

CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-[(4-(2-thienylmethyl)-1-piperazinyl]carbonyl]-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-69-6 CAPLUS

CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-[(4-(2-phenylethyl)-1-piperazinyl]carbonyl]-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-71-0 CAPLUS

CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-[(4-(tetrahydro-2-furanyl)methyl)-1-piperazinyl]carbonyl]-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-73-2 CAPLUS

CN 1-Piperazineacetic acid, 4-[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 863645-74-3 CAPLUS

CN Benzonitrile, 4-[5-acetyl-3-[(4-chlorophenyl)-1-piperazinyl]carbonyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl- (CA INDEX NAME)




RN 863645-75-4 CAPLUS

CN Benzonitrile, 4-[5-acetyl-3-[(2,4-dimethyl-1-piperidinyl)carbonyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl- (CA INDEX NAME)




RN 863645-76-5 CAPLUS

CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-3-[[4-[2-(4-morpholinyl)ethyl]-1-piperazinyl]carbonyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-78-7 CAPLUS

CN Carbamic acid, [1-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 863645-80-1 CAPLUS

CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-[[3-[4-(trifluoromethyl)phenoxy]-1-azetidinyl]carbonyl]-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-81-2 CAPLUS

CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-2-oxo-3-[(3-phenoxy-1-azetidinyl)carbonyl]-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-83-4 CAPLUS

CN Benzonitrile, 4-[5-acetyl-3-[(6-fluoro-3,4-dihydro-2-methyl-1(2H)-quinolinyl)carbonyl]-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-84-5 CAPLUS

CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-3-[(4-(methoxyimino)-1-piperidinyl]carbonyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 863645-85-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-3-pyridinyl]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 863645-88-9 CAPLUS

CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-3-[(4-(2-nitrophenyl)-1-piperazinyl]carbonyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)



RN 863646-00-8 CAPLUS
 CN 3-Pyridinecarboxamide, 5-acetyl-4-(4-cyanophenyl)-1,2,3,4-tetrahydro-6-methyl-N-(4-methyl-1-piperazinyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-
 (CA INDEX NAME)



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2004:203810 CAPLUS
 DN 140:235612
 TI Preparation of dihydropyridinones as human neutrophil elastase (HNE) inhibitors
 IN Gielen, Heike; Li, Volkhart Min-Jian; Rosentreter, Ulrich; Schlemmer, Karl-Heinz; Allerheiligen, Swen; Telan, Leila; Baerfacker, Lars; Keldenich, Joerg; Fitzgerald, Mary F.; Nash, Kevin; Albrecht, Barbara; Meurer, Dirk
 PA Bayer Healthcare A.-G., Germany
 SO PCT Int. Appl., 166 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004020410	A2	20040311	WO 2003-EP9108	20030818
	WO 2004020410	A3	20040422		
		W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
		RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,		

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2496815 A1 20040311 CA 2003-2496815 20030818
 AU 2003293356 A1 20040319 AU 2003-293356 20030818
 EP 1554246 A2 20050720 EP 2003-790904 20030818
 EP 1554246 B1 20070822
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2006503820 T 20060202 JP 2004-532090 20030818
 ES 2293077 T3 20080316 ES 2003-790904 20030818
 US 20060100207 A1 20060511 US 2005-525608 20051013
 US 7230017 B2 20070612
 PRAI GB 2002-19894 A 20020827
 GB 2002-21143 A 20020912
 WO 2003-EP9108 W 20030818

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 140:235612

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein A = hetero/aryl; R1, R2, R3 = independently H, halo, NO₂, CN, CF₃, OCF₃, (un)substituted alkyl, OH and derivs., R4 = alkenoxycarbonyl, hydroxycarbonyl, CN, (un)substituted alkylcarbonyl, alkoxy carbonyl, alkyl/cycloalkyl/N-(heterocyclyl)/mono/di/aminocarbonyl; R5 = alkyl; R6 = H, CN, cycloalkyl/alkyl/aminocarbonyl, cycloalkylcarbonyl, arylcarbonyl, hydroxycarbonyl, alkenoxycarbonyl, aryloxycarbonyl, (un)substituted mono/di/aryl/aminocarbonyl, alkylcarbonyl, alkoxy carbonyl, or R6 = 4-carbonylpiperazinyl and derivs., 4-carbonylmorpholinyl, etc.; R7 = H, halo, NO₂, CN, CF₃, OCF₃, (un)substituted alkyl, alkoxy; Y₁, Y₂, Y₃, Y₄, Y₅ = independently CH or N; and their salts, hydrates, and/or solvates, and their tautomeric forms] were prepared as human neutrophil elastase (HNE) inhibitors. For example, II was prepared by cyclocondensation of III (preparation given) with 4-formylbenzonitrile and 2-cyanoacetamide in the presence of EtOH/piperidine, followed by reaction with water in acetic acid. In an in vitro assay, I inhibited HNE with IC₅₀ values within the range of 5 nM - 5 μM. Thus, I are useful for treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.


IT 668999-20-0P, Ethyl 4-(4-cyanophenyl)-2-methyl-6-oxo-5-[(1-pyrrolidinyl)carbonyl]-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate 668999-23-3P, Ethyl 4-(4-cyanophenyl)-2-methyl-5-[(4-morpholinyl)carbonyl]-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate 668999-24-4P, Ethyl 4-(4-cyanophenyl)-2-methyl-6-oxo-5-[(1,3-thiazolidin-3-yl)carbonyl]-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate 668999-27-7P, Ethyl 4-(4-cyanophenyl)-2-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]-6-oxo-1-[3-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxylate 668999-31-3P, 4-[5-Acetyl-6-methyl-3-[(4-morpholinyl)carbonyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-4-pyridinyl]benzonitrile 668999-81-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(human neutrophil elastase inhibitor; preparation of dihydropyridinones as human neutrophil elastase inhibitors)


RN 668999-20-0 CAPLUS

CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-5-(1-pyrrolidinylcarbonyl)-1-[3-(trifluoromethyl)phenyl]-, ethyl ester
(CA INDEX NAME)




RN 668999-23-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-5-(4-morpholinylcarbonyl)-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester
(CA INDEX NAME)




RN 668999-24-4 CAPLUS

CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-5-(3-thiazolidinylcarbonyl)-1-[3-(trifluoromethyl)phenyl]-, ethyl ester
(CA INDEX NAME)




RN 668999-27-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]-6-oxo-1-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 668999-31-3 CAPLUS

CN Benzonitrile, 4-[5-acetyl-1,2,3,4-tetrahydro-6-methyl-3-(4-morpholinylcarbonyl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-4-pyridinyl]- (CA INDEX NAME)




RN 668999-81-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[(4-acetyl-1-piperazinyl)carbonyl]-4-(4-cyanophenyl)-1,4,5,6-tetrahydro-2-methyl-6-oxo-1-[3-

10/589907

(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log h			
COST IN U.S. DOLLARS	SINCE FILE	TOTAL	
	ENTRY	SESSION	
FULL ESTIMATED COST	11.78	215.13	
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL	
	ENTRY	SESSION	
CA SUBSCRIBER PRICE	-1.64	-3.28	

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:47:44 ON 22 OCT 2009